Our results are consistent with these studies, suggesting that NSCLC EGFR mutation positive patients with BIM deletion polymorphism benefit less from EGFR TKI therapy in terms of PFS and OS compared to patients without BIM deletion polymorphism. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.